Dr. Clive A. Meanwell Chairman and Chief Executive Officer
Clive Meanwell, M.D., Ph.D., has been a director and served as our principal executive officer, or as one of our principal executive officers, continuously since 1996. He has served as our Chief Executive Officer since August 2004, and he served as our President from August 2004 to December 2004, as our Executive Chairman from September 2001 to August 2004 and as our Chief Executive Officer and President from 1996 to September 2001. From 1995 to 1996, Dr. Meanwell was a Partner and Managing Director at MPM Capital, L.P., a venture capital firm. From 1986 to 1995, Dr. Meanwell held various positions at Hoffmann-La Roche, Inc., a pharmaceutical company, including Senior Vice President from 1992 to 1995, Vice President from 1991 to 1992 and Director of Product Development from 1986 to 1991. Dr. Meanwell currently serves as a director of both Endo Pharmaceuticals and BB Biotech. Dr. Meanwell received an M.D. and a Ph.D. from the University of Birmingham, United Kingdom.
Bill O'Connor has been our Chief Accounting Officer since February 2008. He joined The Medicines Company in April 2006 as Vice President and Controller. Before joining the MDCO, Bill worked at Eyetech Pharmaceuticals as the VP of Finance. Prior to that Bill work for Trophix a Biotech company that specializes in pain medications. In addition, Bill has 14 years of experience in the public accounting sector. Bill is a CPA and holds Bachelors Degree in Accounting from Farleigh Dickinson University.
Mr. John P. Kelley President and Chief Operating Officer
John P. Kelley has been our President and Chief Operating Officer since December 2004 and a director since February 2005. Prior to joining us, Mr. Kelley held a series of positions at Aventis, an international pharmaceutical company. From September 2003 until September 2004, Mr. Kelley served as Senior Vice President, Global Marketing and Medical at Aventis, where he was accountable for worldwide brand management of Aventis' core strategic brands and managed strategic alliances with partner companies. From September 2002 to September 2003, he served as Senior Vice President, Strategic Risk Officer for Aventis, advising the Management Board and Chief Executive Officer. From January 2000 to September 2002, Mr. Kelley served as Vice President, Head of Strategic Development of Aventis where he was responsible for leading the strategic planning process of the pharmaceutical division of Aventis as well as merger and acquisition activity. Prior to the formation of Aventis, he served as a Vice President, Commercial Director, U.S. at Hoechst Marion Roussel, Inc., a life sciences firm focused on pharmaceuticals and agriculture, from March 1998 through December 1999. Prior to that, Mr. Kelley served as Vice President of Marketing of Hoechst Marion Roussel from 1995 to 1998. Mr. Kelley received a B.A. from Wilkes University and an M.B.A. from Rockhurst University.
Mr. Glenn Sblendorio Executive Vice President and Chief Financial Officer
Glenn P. Sblendorio has been our Chief Financial Officer and Executive Vice President since March 2006. Prior to joining the Company, Mr. Sblendorio was Executive Vice President and Chief Financial Officer of Eyetech Pharmaceuticals, Inc. until it was acquired by OSI Pharmaceuticals, Inc. in November 2005. From July 2000 to February 2002, Mr. Sblendorio served as Senior Vice President of Business Development for the Company. From 1998 to July 2000, Mr. Sblendorio was the Chief Executive Officer and Managing Director of MPM Capital Advisors, LLC, an investment bank specializing in healthcare related transactions. Mr. Sblendorio's pharmaceutical experience also includes 12 years at Hoffmann-LaRoche, Inc., a pharmaceutical company, in a variety of senior financial positions, including Chief Financial Officer of Roche Molecular Systems and Head of Finance-Controller for Amgen/Roche Europe. Mr. Sblendorio received his B.B.A. in accounting from Pace University and his M.B.A. in Finance from Fairleigh Dickinson University.
Mr. Paul M. Antinori Senior Vice President and General Counsel
Paul M. Antinori, J.D., has been our General Counsel since May 2002 and has been a Vice President since August 2004. From March 1998 to April 2002, Mr. Antinori was General Counsel and a consultant to Physician Computer Network, Inc., a healthcare information technology company. Prior to March 1998, Mr. Antinori was a partner at Gibbons, Del Deo, Dolan, Griffinger & Vecchione in Newark, New Jersey. Mr. Antinori received his J.D. from the University of Virginia School of Law and his B.A. from Boston College.
Ms. Catharine Newberry Senior Vice President and Chief Human Strategy Officer
Catharine Newberry has been our Senior Vice President Human Resources and Chief Human Strategy Officer since February 2006. Prior to joining us, she held various positions with sanofi aventis, including Deputy Vice President People Development (2005), HR Integration Officer (July 2004-December 2004), Vice President Human Resources Strategy (2003-July 2004). She came to the pharma group after fourteen years with the vaccine business of sanofi pasteur, where she held the positions of Senior Vice President Human Resources (August 1998-2002), Vice President Executive Compensation and Development (1997-July 1998), and Vice President Human Resources for the US business unit (1989-1996). Her career in pharmaceuticals began at SmithKline Beckman, where she held a variety of positions from 1980-1989. Catharine holds a BA in History from Swarthmore College, and a MS in Human Resources Development from American University/NTL.
Ms. Kelli Watson Senior Vice President, Global Communications
Kelli Watson has been our Senior Vice President Global Communications since October 2006. She joined MDCO in January 2006 in support of the Human Strategy function. Prior to joining us, she held various positions with Pfizer Inc, including Vice President Global Human Resources Planning (2002-2006), Vice President Human Resources and Planning for the Corporate Affairs function (1996-2002) and various other Human Resource positions throughout the organization. She was also played leadership roles in Pfizer's acquisition of both Warner- Lambert and Pharmacia, Kelli holds a BA in Psychology and Sociology from Hamline University, and a MA in Industrial Relations from the University of Minnesota.
The Medicines Company—Advancing Innovation in Critical Care
